TR201902435T4 - DGAT1 inhibitör içeren farmasötik bileşimler. - Google Patents

DGAT1 inhibitör içeren farmasötik bileşimler. Download PDF

Info

Publication number
TR201902435T4
TR201902435T4 TR2019/02435T TR201902435T TR201902435T4 TR 201902435 T4 TR201902435 T4 TR 201902435T4 TR 2019/02435 T TR2019/02435 T TR 2019/02435T TR 201902435 T TR201902435 T TR 201902435T TR 201902435 T4 TR201902435 T4 TR 201902435T4
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
compositions containing
dgat1 inhibitors
containing dgat1
inhibitors
Prior art date
Application number
TR2019/02435T
Other languages
English (en)
Inventor
Wen Hong
Kumaraperumal Natrajan
Nause Richard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201902435(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR201902435T4 publication Critical patent/TR201902435T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Mevcut buluş, a) formülün (I) bileşiğinin veya farmasötik olarak kabul edilebilir bir tuzunun terapötik olarak etkili bir miktarını, b) yağlayıcı özellikleri olan bir veya daha fazla, örneğin 1, 2 veya 3 sürfaktan; c) dağıtıcı özellikleri olan bir veya daha fazla, örneğin 1, 2 veya 3 kuru bağlayıcı; d) bir veya daha fazla, örneğin 1, 2 veya 3 dolgu maddesi ve e) bir veya daha fazla, örneğin 1, 2 veya 3 dağıtıcı madde içeren bir farmasötik bileşim ile ilgilidir.
TR2019/02435T 2010-10-14 2011-10-14 DGAT1 inhibitör içeren farmasötik bileşimler. TR201902435T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39310310P 2010-10-14 2010-10-14

Publications (1)

Publication Number Publication Date
TR201902435T4 true TR201902435T4 (tr) 2019-03-21

Family

ID=44908106

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02435T TR201902435T4 (tr) 2010-10-14 2011-10-14 DGAT1 inhibitör içeren farmasötik bileşimler.

Country Status (29)

Country Link
US (5) US20130190354A1 (tr)
EP (1) EP2627319B1 (tr)
JP (1) JP6060081B2 (tr)
KR (1) KR20130100311A (tr)
CN (1) CN103179957B (tr)
AR (1) AR083417A1 (tr)
AU (1) AU2011316003B2 (tr)
BR (1) BR112013008757A2 (tr)
CA (1) CA2813781C (tr)
CL (1) CL2013001001A1 (tr)
CO (1) CO6710915A2 (tr)
DK (1) DK2627319T3 (tr)
EC (1) ECSP13012755A (tr)
ES (1) ES2712064T3 (tr)
GT (1) GT201300096A (tr)
HU (1) HUE043524T2 (tr)
IL (1) IL225434A0 (tr)
MA (1) MA34599B1 (tr)
MX (1) MX2013004162A (tr)
NZ (1) NZ608558A (tr)
PE (1) PE20140375A1 (tr)
PL (1) PL2627319T3 (tr)
PT (1) PT2627319T (tr)
RU (1) RU2595866C2 (tr)
SG (1) SG189078A1 (tr)
SI (1) SI2627319T1 (tr)
TR (1) TR201902435T4 (tr)
WO (1) WO2012051488A1 (tr)
ZA (1) ZA201302108B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2841432A1 (en) * 2012-04-27 2015-03-04 Novartis AG Tetrahydropyran dgat1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN114099496A (zh) 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017084234A1 (zh) * 2015-11-19 2017-05-26 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
AU2019234956A1 (en) * 2018-03-16 2020-10-01 Anji Pharmaceuticals Inc. Compositions and methods for treating severe constipation
AU2019239404B2 (en) 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT861073E (pt) 1995-11-14 2004-10-29 Abbott Gmbh & Co Kg Preparacoes de hormona da tiroide estabilizadas e metodos para prepara-las
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19816070A1 (de) * 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
BR0215193A (pt) * 2001-12-21 2004-11-16 Pfizer Prod Inc Formulações de azitromicina diretamente compressìveis
CA2605300A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
KR101219042B1 (ko) * 2005-12-06 2013-01-07 삼성디스플레이 주식회사 반투과형 액정 표시 장치
US8414921B2 (en) * 2005-12-16 2013-04-09 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CA2643015A1 (en) * 2006-03-06 2007-09-13 Wyeth Tablet formulations and processes
US20070224258A1 (en) 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
AU2007245059B2 (en) * 2006-03-31 2011-07-28 Novartis Ag New compounds
WO2008067257A2 (en) 2006-11-29 2008-06-05 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
CN103641823A (zh) 2007-04-30 2014-03-19 Abbvie公司 二酰甘油o-酰基转移酶1型酶的抑制剂
WO2009048932A2 (en) * 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
HUE049450T2 (hu) * 2009-03-31 2020-09-28 Ligand Pharm Inc Endotelin és angiotenzin II receptor antagonista bifenilszulfonamid glomeruloszklerózis és IgA által kiváltott nefropátia kezelésére
RU2012145950A (ru) * 2010-03-30 2014-05-10 Новартис Аг Применения ингибиторов dgati
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor

Also Published As

Publication number Publication date
MX2013004162A (es) 2014-12-08
AU2011316003B2 (en) 2015-03-19
US20130190354A1 (en) 2013-07-25
ZA201302108B (en) 2013-11-27
JP2013539794A (ja) 2013-10-28
HUE043524T2 (hu) 2019-08-28
BR112013008757A2 (pt) 2020-09-01
DK2627319T3 (en) 2019-03-18
US20180243222A1 (en) 2018-08-30
EP2627319B1 (en) 2018-11-21
ECSP13012755A (es) 2014-01-31
US10646446B2 (en) 2020-05-12
CA2813781A1 (en) 2012-04-19
MA34599B1 (fr) 2013-10-02
PE20140375A1 (es) 2014-03-19
SG189078A1 (en) 2013-05-31
KR20130100311A (ko) 2013-09-10
CN103179957B (zh) 2016-05-18
US20150320687A1 (en) 2015-11-12
RU2595866C2 (ru) 2016-08-27
SI2627319T1 (sl) 2019-04-30
WO2012051488A1 (en) 2012-04-19
AR083417A1 (es) 2013-02-21
PT2627319T (pt) 2019-02-27
US20160374947A1 (en) 2016-12-29
CN103179957A (zh) 2013-06-26
GT201300096A (es) 2014-07-08
US11304907B2 (en) 2022-04-19
AU2011316003A1 (en) 2013-04-11
IL225434A0 (en) 2013-06-27
CO6710915A2 (es) 2013-07-15
PL2627319T3 (pl) 2019-05-31
US20200230062A1 (en) 2020-07-23
RU2013121795A (ru) 2014-11-20
CL2013001001A1 (es) 2013-10-25
JP6060081B2 (ja) 2017-01-11
ES2712064T3 (es) 2019-05-09
NZ608558A (en) 2015-03-27
EP2627319A1 (en) 2013-08-21
CA2813781C (en) 2018-08-07

Similar Documents

Publication Publication Date Title
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
AR082600A1 (es) Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras
BR112013016595A2 (pt) inibidores de neprilisina
EA201270216A1 (ru) Фармацевтический состав
EA200970156A1 (ru) Пиридизиноновые производные
NZ607794A (en) N-acylsulfonamide apoptosis promoters
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
RS53301B (en) TIOACETATE COMPOUNDS, COMPOSITIONS AND USE PROCEDURES
EA201190306A1 (ru) Улучшенная липидная композиция
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2013004242A (es) Sulfonamidas nematocidas.
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
UY33205A (es) Naftiridinas sustituidas y su uso como medicamentos
EA201270590A1 (ru) Ингибиторы акт
BR112014011254A2 (pt) 2-tiopirimidinonas
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
NO20085317L (no) Imidazoazepinonforbindelser